Limited Edition Golden Llama is here! Check out how you can get one. 
Limited Edition Golden Llama is here! Check out how you can get one.
Offering SPR-BLI Services - Proteins provided for free! Offering SPR-BLI Services - Proteins provided for free!
Thank you for choosing ACROBiosystems. Would you rate our product and service？ Thank you for choosing ACROBiosystems. Would you rate our product and service？
Here come GMP Grade Cytokines！Free Sample is available！ Here come GMP Grade Cytokines！Free Sample is available！
A-Z
> 抗体薬物複合体ADC医薬品創薬向けのソリューションサービス
ADC Target Proteins
AGLink® Site-specific Conjugation Kit
The target antigen expressed on the surface of tumor cells is a key factor for ADCs to recognize tumor cells and guide the cytotoxic payload into the cancer cells. Therefore, selecting an appropriate target antigen is a primary consideration in ADCs design. Ideal antigens should exhibit specific expression, non-secretion, and favorable internalization properties.
We have successfully developed a suite of over 90 high-quality ADCs target proteins, encompassing a variety of species including Human, Mouse, Cynomolgus Monkey, and Rat, each equipped with diverse tags. These proteins with high purity and robust bioactivity, suitable for immunization, antibody screening, species validation, quality control, pharmacokinetic studies, and diverse applications.
ADCs conjugation methods are commonly categorized as random or site-specific. Among these, site-specific conjugation is increasingly preferred due to its ability to yield conjugated drugs with high uniformity and enhanced safety profiles.
Glycan-mediated conjugation is a type of site-specific conjugation that exploits the conserved N297 glycosylation site in the Fc region of the antibody. Because this site is located away from the antigen-binding domain, conjugation does not interfere with the antibody’s binding affinity. Furthermore, this approach eliminates the need for antibody engineering modifications, offering greater convenience and versatility while significantly accelerating early-stage research.
In collaboration with Glyco-Therapy Biotechnology Co., Ltd., we have developed the AGLink® DAR2&4 site-specific conjugation kit. Based on Glyco-therapy's YTConju™ conjugation platform, the kit facilitates efficient conjugation of various payloads, including toxin (MMAE), reactive functional groups (Tz/DBCO), and detection labels (Biotin). Designed to empower early-stage research and biological experiments in the field of conjugated drugs.
| Molecule | Cat. No. | Product Description | Preorder/Order |
|---|
FcR Protein—Fc Receptor Affinity Validation
The efficacy of antibody-drug conjugates (ADCs) is determined not only by the ability of their Fab fragments to bind tumor-associated antigens but also by the interaction between their Fc fragments and Fc receptors. Fc-mediated effector functions—such as antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and antibody-dependent cellular phagocytosis (ADCP)—play a crucial role in the elimination or suppression of tumor cells.
Additionally, the affinity of the Fc fragment for the neonatal Fc receptor (FcRn) is a key predictor of an antibody’s half-life. Therefore, optimizing antibody structures and selecting candidates with ideal Fc receptor affinity are essential strategies in the development of therapeutic antibodies.
We offer a comprehensive collection of Fc receptor products, including FcRn, FcγR, and their commonly studied mutants. Leveraging our extensive protein product resources and activity analysis experience, we can also provide high-quality SPR & BLI affinity testing services upon receiving your sample. To support your research, we also supply all necessary high-quality Fc receptor proteins free of charge for these experiments.
In the development of ADCs, the linker structure impacts stability, homogeneity, cytotoxic potency, tolerability, and pharmacokinetics (PK). Therefore, selecting the appropriate linker is crucial for optimizing the therapeutic potential and safety of ADCs.
Linkers are typically classified as cleavable or non-cleavable based on their cleavage mechanism. Current ADCs research primarily focuses on cleavable linkers, with cathepsin-cleavable linkers being the most widely used and extensively studied. Additionally, several other linker-cleaving enzymes are under investigation.
For the screening and validation of linkers for ADCs, we have developed a series of proteases specialized in linker cleavage, encompassing Cathepsin B, Cathepsin L, Cathepsin S, MMP-2, MMP-7, MMP-9, β-glucuronidase, β-galactosidase.
| Molecule | Cat. No. | Product Description | Preorder/Order |
|---|
ADCs have a more complex structure compared to traditional small molecule drugs and antibody drugs, resulting in higher drug heterogeneity, which makes its PK studies more complex. Analytes for ADCs typically encompass total antibodies (both conjugated and unconjugated with cytotoxic payloads, DAR≥0); conjugated antibodies (antibody conjugated to payload, DAR≥1), the antibody-conjugated drug, free drugs, and their analogs. The quantification of total antibodies and conjugated antibodies commonly employs ELISA (Enzyme-linked Immunosorbent Assay), while the analysis of antibody-conjugated drugs, free drugs, and their metabolites frequently involves LC-MS (Liquid Chromatograph Mass Spectrometer).
In order to tackle the challenges and complexities associated with the PK analysis of ADCs, we have introduced a comprehensive range of products and services tailored for PK research. These offerings encompass biotinylated proteins, streptavidin (SA) series products, anti-Payload antibodies, anti-idiotypic antibodies, anti-idiotypic antibodies development services, PK method development, validation and transfer, kit development services and more.
Featured Products: Anti-payload Antibodies
| Molecule | Cat. No. | Product Description | Preorder/Order |
|---|
![[Flyer]Fucntional Cell Lines and Development Service](https://www.acrobiosystems.com/static/main/images/ADC_Antibody/1223_04.png)
This web search service is supported by Google Inc.
アクロバイオシステムズの公式アカウント
